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Abstract
Background: The methods used for sample selection and processing can have a strong influence on the expression
values obtained through microarray profiling. Laser capture microdissection (LCM) provides higher specificity in the
selection of target cells compared to traditional bulk tissue selection methods, but at an increased processing cost. The
benefit gained from the higher tissue specificity realized through LCM sampling is evaluated in this study through a
comparison of microarray expression profiles obtained from same-samples using bulk and LCM processing.
Methods: Expression data from ten lung adenocarcinoma samples and six adjacent normal samples were acquired using
LCM and bulk sampling methods. Expression values were evaluated for correlation between sample processing methods,
as well as for bias introduced by the additional linear amplification required for LCM sample profiling.
Results: The direct comparison of expression values obtained from the bulk and LCM sampled datasets reveals a large
number of probesets with significantly varied expression. Many of these variations were shown to be related to bias
arising from the process of linear amplification, which is required for LCM sample preparation. A comparison of
differentially expressed genes (cancer vs. normal) selected in the bulk and LCM datasets also showed substantial
differences. There were more than twice as many down-regulated probesets identified in the LCM data than identified
in the bulk data. Controlling for the previously identified amplification bias did not have a substantial impact on the
differences identified in the differentially expressed probesets found in the bulk and LCM samples.
Conclusion:  LCM-coupled microarray expression profiling was shown to uniquely identify a large number of
differentially expressed probesets not otherwise found using bulk tissue sampling. The information gain realized from the
LCM sampling was limited to differential analysis, as the absolute expression values obtained for some probesets using
this study's protocol were biased during the second round of amplification. Consequently, LCM may enable investigators
to obtain additional information in microarray studies not easily found using bulk tissue samples, but it is of critical
importance that potential amplification biases are controlled for.
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Background
Microarray gene expression profiling is extensively used to
study the etiology of disease and identify differential
expression between two states. This high-throughput tech-
nology simultaneously measures expression levels in
thousands of transcripts, providing a snapshot of the
molecular makeup of a sample. The resulting data are rep-
resentative of the cumulative expression of all cell types
found in the sample. To increase specificity of the micro-
array expression signatures, investigators have used laser
capture microdissection (LCM) for cell-collection prior to
microarray hybridization. LCM is a precise extraction
method that targets and extracts single cells from a sample
[1-7]. Using this technology, a homogeneous collection of
thousands of cells can be acquired and used to generate an
accurate gene expression profile for a target tissue.
The perceived benefit of using LCM cell-sampling instead
of bulk tissue-sampling for microarray analysis is bal-
anced by the additional time and expense this method
requires. LCM enables the precise extraction of target cells
from a tissue sample consisting of a heterogeneous mix-
ture of cell types. Bulk tissue sampling is faster and less
expensive than LCM, however, sampled tissues often con-
sist of a mixture of target and contaminating cell types.
The process of LCM cell selection often generates low
yields of RNA. Consequently, LCM-coupled microarray
studies will use an additional round of RNA amplification
(linear amplification) prior to microarray hybridization
[5,8-10], which in some instances has been shown to bias
the resulting expression values [11,12]. Comparative stud-
ies can demonstrate biological and methodological differ-
ences in expression data obtained by LCM cell-sampling
experiments and bulk tissue-sampling experiments. Such
studies will be intrinsically dependent on the tissue-type
evaluated, as the constituent mixture of cell-types com-
prising the tissue will affect the bulk tissue-sampling
expression data. Results from these analyses can be used
to guide future experimental design, increasing the return
for the research investment.
This study describes the first known comparison of micro-
array data generated from lung adenocarcinoma tumor
cells and adjacent normal cells, acquired by LCM cell-
sampling and bulk tissue-sampling. Lung cancer is the
leading cause of cancer death in the U.S. in both men and
women [13]. Its heavy burden on society has fueled sub-
stantial research and led to the dissemination of multiple
public microarray datasets generated by bulk tissue-sam-
pling protocols. Laser capture microdissection enables the
specific collection of malignant epithelial cells within the
lung adenocarcinoma tumor samples, while minimizing
contamination by benign cells, stromal cells, and cells
associated with other lesions. The results presented in this
study should provide investigators with the information
necessary to critically assess the value of LCM-coupled
microarray expression profiling of lung adenocarcinoma,
and determine if this approach would benefit their
research goals. These data also provide a context by which
LCM-cell-sampled expression profiling can be evaluated
and compared to existing bulk tissue-sampled studies.
Microarray expression data were generated from LCM-
cell-sampled and bulk tissue-sampled specimens acquired
from matched cases, for ten adenocarcinomas and six
adjacent-benign samples. To provide a reference to assess
potential bias arising from the additional amplification
step, RNA from two adenocarcinomas and two benign
samples, acquired by bulk tissue-sampling, were linear
amplified and hybridized to microarrays. The direct com-
parison of expression values revealed a substantial
number of probesets with significantly altered expression
levels between the bulk and LCM datasets. Evaluation of
the linear amplified bulk data, however, showed many of
the alterations are likely caused by an amplification bias,
and not by differences in the cell populations profiled.
Conversely, a comparison of differentially expressed
probesets (cancer vs. normal) identified in the bulk and
LCM datasets, showed a considerably higher number of
differentially expressed genes were found in the LCM data.
Interpreted in context of the linear amplified bulk data,
this observation appears to be predominantly unrelated
to the amplification bias and suggests LCM increases the
sensitivity of detecting differentially expressed genes in
the microarray data.
Methods
Samples
Fresh frozen tissue samples were obtained from the Mayo
lung tissue bank for ten patients with stage IIIA or IIIB
adenocarcinoma of the lung and with surgical tumor
resection. Normal lung tissue adjacent to tumor in six
patients were also obtained from the Mayo lung tissue
bank. All samples were fast frozen within 30 minutes after
resection and stored in -80 °C. All cases were first
reviewed by a pathologist (MC) for their diagnosis accu-
racy and adequacy for a microarray study. Normal and
tumor samples were selected if there was sufficient mate-
rial to microarray profile both laser capture microdis-
sected samples and bulk tissue samples. The use of the
tissue for the study was approved by Mayo Foundation
Institutional Review Board.
LCM
For each patient, a pathologist assessed an H&E stained
slide from each frozen tumor block (and normal block if
needed). Fifteen sections (10 μm thick) of the chosen
tumor and normal blocks were cut in a cryostat and
placed on slides by the Tissue and Cellular Molecular
Analysis (TACMA) core facility (Mayo Clinic, Rochester,BMC Medical Genomics 2009, 2:13 http://www.biomedcentral.com/1755-8794/2/13
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MN) under Rnase free conditions. Slides were kept at -
80°C and immediately stained with cresyl violet using an
Ambion LCM staining kit (#1935) protocol. The desired
area of tissue was microdissected from the slide within 30
minutes of staining using Arcturus LCM caps and micro-
scope. The cap was placed on a tube that contained 75 μl
of digestion buffer (RLT with BME from the Qiagen RNe-
asy micro kit #74004). The tube was inverted so the buffer
covers the cap, vortexed at a medium speed for one
minute and incubated at room temperature for 5 minutes.
The tube was then centrifuged and the cap discarded. The
samples were stored at -80°C until ready for RNA isola-
tion. This procedure was repeated on the next slide for the
case until a total of 5000 pulses were captured for that
case. Each pulse targeted 3–5 cells. Due to tumor cell ple-
omorphism, it is difficult to standardize the number of
cells captured per pulse. The number of slides used per
case varied from 2 to 10, as every case and every tumor
block had different sized tumors.
RNA is isolated according to the Qiagen RNeasy micro kit
protocol (Qiagen, Valencia CA) with the following modi-
fications. All of the tubes from the same sample were
pooled together and 75 μl of 70% ethanol was added for
each tube in the pool. The sample was applied to the col-
umn 700 μl at a time and spun according to protocol until
the whole sample was applied. The RPE step was repeated
to get rid of excess salt that may have accumulated due to
multiple applications of sample to the column (depend-
ing on how many caps were needed per sample). The col-
umn was incubated with elution water for 5 minutes prior
to spinning. The amount of RNA in each case was quanti-
tated using the Quant-iT™ RiboGreen kit (Invitrogen
Carlsbad, CA). The quality of the RNA was assessed using
an Agilent 2100 Bioanalyzer in the Advanced Genomics
Technology Center (Mayo Foundation). RIN (RNA integ-
rity number) of 7 or greater was required to proceed to the
linear amplification step.
Ten nanograms of RNA was linear amplified using the
Affymetrix protocol (Genechip Expression Analysis Tech-
nical Manual Section 2) (Affymetrix kit # 900432 and
Ambion kit #1334). The cRNA yield ranged from 84 μg to
134 μg, with a mean of 120 μg, per sample. Of each sam-
ple, 15 μg was then hybridized to the Affymetrix HU 133
plus 2.0 chips in the Advanced Genomics Technology
Center using the same protocol.
Bulk
For the bulk samples, the same blocks had 50 μm of tissue
cut by the TACMA lab directly into a tube for tumor cases
and 1000 μm of tissue for normal. These samples were
kept frozen at -80°C until RLT buffer was added. The sam-
ples were homogenized using a mechanical homogenizer
for 30 seconds and the RNA isolated using the RNeasy kit
protocol. Once the RNA was isolated, it was evaluated
using the Agilent and Ribogreen assays described above.
The 1.4 μg of sample was then processed and hybridized
(15 μg) onto the HU 133 plus 2.0 chip. From four sam-
ples, an additional 10 ng of RNA was linear amplified (as
described for LCM) and then processed on the microarray
chips. The cRNA yields for these four samples ranged from
130 μg to 145 μg, with a mean of 136 μg.
Data preprocessing and analysis
The Affymetrix U133 Plus 2.0 gene chips were read using
a GeneChip Scanner 3000 7G. Raw expression CEL files
were analyzed using the dChip invariant set normaliza-
tion procedure, with PM-only modeling. Expression val-
ues were log2 transformed.
For all comparisons, a priori thresholds were imposed to
restrict the analysis to large changes in expression occur-
ring beyond the scope of background signal. Two selec-
tion criteria were used when comparing expression values
from A and B:
(i) ΔA, B ≥ log2 2  (denotes a 4× change in expression)
(ii) max(A, B) ≥ log2 8  (ensured the higher value exceeded
background levels)
To estimate the effect acquisition methods have on the
selection of differentially expressed probesets, concord-
ance between bulk and LCM rank-ordered differential
probeset lists was calculated. Concordance was used to
measure the agreement in ordered lists based on an abso-
lute threshold, where probesets ranked above the absolute
threshold on both lists were considered "in agreement"
and the remainder "not in agreement". Analysis was per-
formed over a range of thresholds and the results plotted.
Probesets were rank ordered by the magnitude of the dif-
ference in log2 expression values, while maintaining the
same selection criteria used throughout the study (Δ ≥ log2
2; max exp value ≥ log2 8). Comparisons were initially
conducted on the cases with linear amplified bulk sam-
ples, and subsequently performed on the complete data-
set.
All statistical tests were computed using the R free soft-
ware package http://www.r-project.org/.
Probeset distance to 3' end of transcript
Using Affymetrix's NetAffx Annotation File (Aug, 2007),
the corresponding RefSeq transcripts, where annotated,
were identified for all probesets. The sixth probe from
each probeset was sequence-compared to its RefSeq tran-
script. Probesets for which the sixth probe mapped to the
corresponding RefSeq transcript with 100% identity, were
selected for further analysis. The distance between the 5'BMC Medical Genomics 2009, 2:13 http://www.biomedcentral.com/1755-8794/2/13
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end of the sixth probe sequence and the transcript 3' end,
minus any terminal poly-A repeat, was computed in
bases. Distance values were determined for two groups: (i)
all probesets with an average expression greater than
log28, and (ii) all probesets with significant alterations in
expression between bulk and linear amplified bulk sam-
ples. Density plots for the two groups were computed
using the R 'density' function, and independence in the
distributions tested using the Kolmogorov-Smirnov test.
For these probesets, the corresponding RefSeq transcript
was scanned for poly-A repeats of at least six adenines in
length at the 3' terminus.
Results
Comparison of expression data between sampling 
methods
The direct comparison of microarray data generated from
bulk and LCM-sampled tumor and adjacent benign tissue
identified a significant number of probesets with highly
variant expression. All comparisons were limited to large
changes in expression (4-fold or higher) to minimize
type-I error arising from cross-hybridization and platform
measurement variability. Results from the matched-sam-
ple comparisons between bulk and LCM data, stratified by
cancer or normal status, are plotted in Figure 1. When
comparing the bulk data to the LCM data, significant
changes in expression levels were found for an average of
749 probesets across all six normal tissues samples and
684 probesets across all ten cancer tissues samples. Many
consistent alterations were identified, with 114/749
probesets altered in all six normal tissue samples, and
153/684 probesets altered in all ten of the cancer tissue
samples. The changes identified in normal and cancer tis-
sues were compared using a Student's T-test (α = 0.05),
with no statistically-significant difference identified (p =
0.46).
The preceding comparisons were repeated using two alter-
native methods to determine how robust the findings
were. First, the average probeset expression value across
all six bulk normal samples was compared to the average
probeset expression value across all six LCM normal sam-
ples, and likewise for the cancer samples, identifying 387
probesets in normal tissue and 500 probesets in cancer tis-
sue with significantly varied expression levels. Second, a
Bonferroni corrected T-test (α = 0.05) was used to com-
pare the microarray groups identified 577 probesets in
The average probeset expression values in the LCM microarrays plotted against the average in the bulk microarrays, for nor- mal and cancer tissues Figure 1
The average probeset expression values in the LCM microarrays plotted against the average in the bulk micro-
arrays, for normal and cancer tissues. The selection thresholds for determining significantly varied expression are noted 
(white lines). Most variant probesets exhibited higher expression in the bulk microarrays versus the LCM microarrays, with 
387 probesets in the normal tissue and 500 probesets in the cancer tissue displaying significantly different expression values in 
the LCM vs. bulk microarrays. The overlaid box-plots illustrate the distribution of variant probesets identified in the individual 
matched-case comparisons. No statistically significant differences in the number of altered probesets were found between nor-
mal lung tissue and lung adenocarcinoma.
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normal tissue and 3616 probesets in cancer tissue, with
significantly divergent expression.
To estimate whether the second round of RNA amplifica-
tion, required for LCM sample processing, induced a bias
in the expression data, RNA from two normal-bulk and
two cancer-bulk tissue samples were linearly amplified.
Using the two-sample average probeset expression values
from the linear-amplified bulk, bulk, and LCM microar-
rays, the previous comparisons were repeated. As evident
in Figure 2, very few probesets were identified with sub-
stantially different expression levels in the LCM samples
compared to the linear amplified bulk samples. However,
when comparing expression levels in the LCM samples to
that in the bulk samples, or when comparing expression
levels in the linear-amplified bulk samples with that in the
bulk samples, there were substantially more divergent
probesets identified. These observations were consistent
in both the normal samples (Figure 2a) and cancer sam-
ples (Figure 2b). A further elaboration of these observa-
tions is presented in Additional file 1.
Probeset distance to 3' end of transcript relative to gene 
polyA tail
The second round of the linear amplification method used
to process the LCM samples includes a random priming
step which may induce a bias in the amplified expression
level of probesets distant from the target gene's 3' end [14].
To test for this 3' bias effect, 318 probesets with expression
levels significantly different in the bulk and linear ampli-
fied bulk microarrays (combined normal and cancer tis-
sue), were evaluated. A total of 212/318 probesets
possessed an Affymetrix annotated RefSeq transcript. The
probeset to transcript 3' end distance was calculated and a
density plot of the probeset distances (in bases) was gener-
ated (Figure 3). A second curve was generated for a control
population of probesets with an average expression level
greater than or equal to 8 (n = 12,634). Using a Kol-
mogorov-Smirnov test, the two density distributions were
shown to be statistically different (p < 0.0001), with the dis-
tribution for the 212 selected probesets shifted to the right,
further from the transcripts 3' end. False discovery analysis
based on the selection of 100 random probeset popula-
tions of size 212, and compared to the control population,
yielded Kolmogorov-Smirnov test parameters with a
median p-value of 0.68 and a 90th percentile p-value of
0.22. Based on the false discovery analysis, the increase in
probeset distance from the gene 3' end observed for the
probesets with linear amplification bias appears to be real
and not an artifact of subset selection.
Impact of LCM on identification of differentially expressed 
genes
A common objective of many microarray studies is the
selection of differentially expressed genes; genes with sig-
Probesets with significant changes in expression level  between bulk, LCM, and linear amplified bulk samples Figure 2
Probesets with significant changes in expression level 
between bulk, LCM, and linear amplified bulk sam-
ples. There is a similar distribution of overlapping probesets 
between the bulk samples and either of the amplified samples 
(LCM or Linear Amplified Bulk). Between amplified samples, 
there are very few probesets with significant changes in 
expression level, suggesting most of the changes observed 
between bulk and LCM are a by-product of an amplification 
protocol bias. These observations were consistent in both 
(A) normal tissue samples, and (B) cancer tissue samples.
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Density plot of probeset distance to gene 3' end, for  probesets with observed amplification bias (solid line) and a  control set of all highly expressed (≥ log28) probesets  (dashed line) Figure 3
Density plot of probeset distance to gene 3' end, for 
probesets with observed amplification bias (solid 
line) and a control set of all highly expressed (≥ log28) 
probesets (dashed line). The biased probesets have a sta-
tistically different density distribution, shifted to the right, 
further from the gene's 3' end.BMC Medical Genomics 2009, 2:13 http://www.biomedcentral.com/1755-8794/2/13
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nificantly altered expression levels between normal and
disease states. To determine whether LCM cell-sampling
significantly effects the identification of differentially
expressed genes, comparisons of up-regulated and down-
regulated genes, identified using the bulk and LCM data-
sets, were carried out. Differential expression was com-
puted using the average probeset expression across all cases.
A total of 110 upregulated probesets were identified in the
LCM dataset and 122 in the bulk dataset. Of these, 68
probesets were identified in both datasets. There were also
378 down-regulated probesets identified in the LCM data-
set and 181 in the bulk dataset. Of these, 158 probesets
were identified as down-regulated in both datasets. A list of
the differentially expressed probesets identified in the bulk
and LCM datasets is provided in Additional file 2.
To estimate the effect of the amplification process bias on
the selection of differentially expressed probesets, the
analysis was repeated using the two-sample average values
for the bulk, LCM, and linear amplified samples. In the
bulk data, 297 up-regulated probesets were identified,
238 in the linear amplified bulk data, and 217 in the LCM
data. As illustrated in Figure 4a, 111 up-regulated
probesets were found in all three datasets. There were sub-
stantially more probesets commonly identified between
the bulk and linear amplified bulk samples, than between
the bulk and LCM sample sets, or between the linear-
amplified bulk and LCM sample sets. A total of 339 down-
regulated probesets were identified in the bulk dataset,
278 in the linear amplified bulk dataset, and 565 in the
LCM dataset. Of these, there were 184 probesets com-
monly identified as down-regulated in all three datasets
(Figure 4b). A further elaboration of these observations is
presented in Additional file 1.
To further evaluate the effect amplification bias has on the
selection of differentially expressed genes, probesets
expressed at significantly different levels in the bulk and
linear amplified bulk samples were compared to
probesets possessing cancer-to-normal differential expres-
sion levels in either the LCM or the bulk samples, but not
both. The results are reported in Table 1. In general, the
overlap between these two datasets was small. The largest
overlap was for probesets uniquely identified as up-regu-
lated in the bulk dataset. Detailed review of the individual
expression profiles for these probesets revealed attenuated
expression levels in the LCM and linear amplified bulk
samples, suggesting the reason the probesets were not
identified as upregulated in the LCM samples is a direct
consequence of an amplification process bias (see Addi-
tional file 1 for more details).
Impact of LCM on the ranking of differentially expressed 
genes
The impact LCM cell-sampling has on the relative rank-
ings of differential probesets was also examined, by calcu-
lating the concordance between differentially expressed
probeset rankings in the bulk and LCM datasets. A sliding
threshold was used to select for the top 10, to the top 100
differentially expressed probesets. Probesets previously
identified as up- or down-regulated were ranked by the
magnitude of expression value change. The ranking con-
cordance values were plotted against the selection thresh-
olds, with independent response curves generated for up-
regulated and down-regulated probesets. As illustrated in
Figure 5a, the up-regulated probesets identified from the
average expression levels across all cases, showed dimin-
Overlap of identified probesets with cancer to normal differ- ential expression in the bulk, LCM, and linear amplified bulk  datasets Figure 4
Overlap of identified probesets with cancer to nor-
mal differential expression in the bulk, LCM, and lin-
ear amplified bulk datasets. The number of upregulated 
probesets (a) identified is consistent between datasets, with 
the closest agreement between bulk and linear amplified bulk 
samples. For down-regulated probesets (b), there remains a 
tight association between bulk and linear amplified bulk sam-
ples. In the LCM samples the number of observed down-reg-
ulated probesets is substantially higher than that observed in 
either the bulk or linear amplified bulk samples.
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ishing levels of concordance as the threshold for selection
was increased. This trend was not observed for the down-
regulated probesets. Concordance values for both upregu-
lated and down-regulated probesets converged to approx-
imately 55%.
The impact linear amplification has on the ranking of dif-
ferentially expressed probesets was also evaluated.
Response curves for rank concordance were computed for
the differentially expressed probesets identified from the
two-case average expression values in bulk, linear ampli-
fied bulk and LCM datasets (Figure 5b). The highest con-
cordance (70%–80%) existed between bulk and linear
amplified bulk datasets, for both up-regulated and down-
regulated probesets. A smaller concordance was found for
up-regulated probesets identified in the linear amplified
bulk and LCM datasets (~60%). The concordance
between up-regulated probesets identified in the bulk and
LCM datasets was smaller yet (~50%). Concordance
between down-regulated probesets identified in the LCM
dataset and either the bulk or linear amplified bulk data-
sets, had the lowest values (40%–50%). In all measures of
concordance, no consideration was given to the absolute
rank; probesets were assigned a binary status of selected or
not-selected according to their rank and the threshold
being used. Overall, the concordance values reaffirmed
the tight association between the bulk and linear ampli-
fied bulk differentially expressed probesets, and the lack
of a linear amplification bias effect on the selection of dif-
ferentially expressed probesets.
Discussion
Comparative analysis of microarray data generated from
LCM-cell-sampled and bulk tissue-sampled matched cases
revealed many significant changes in expression levels
between the two datasets. The discrepancies identified in
these datasets highlight two main observations regarding
the LCM process and resulting expression data. First,
when the absolute gene expression levels are compared
between LCM and bulk microarrays there are many signif-
icant differences identified. These variations in gene
expression correlate with the second round of linear
amplification, and do not appear to be related to the cell
populations sampled. Second, substantially more down-
regulated genes are uniquely identified in the LCM dataset
than identified in the bulk dataset (Figure 4). This obser-
vation appears to be independent of the bias associated
with the second round of amplification, and may reflect
differences in cell population. An evaluation of replicate
microarrays showed the inherent variability of the LCM
amplified microarrays to be marginally higher than found
for bulk tissue Affymetrix microarrays (see Additional file
1). While there have been several studies which evaluated
LCM-coupled microarray analyses, none have reported
the above observations in lung or lung adenocarcinoma
[11,12,15-18].
The direct comparison of expression data from LCM-cell-
sampled and bulk tissue-sampled microarrays identified a
high number of genes (~650) with significantly different
expression levels. To ascertain whether these changes are
biologically significant, reflecting the expression patterns
of the cell populations sampled, or an artifact arising from
the LCM process, the expression of these genes in linear
amplified bulk samples were examined. Approximately
two-thirds of the variant probesets identified between the
bulk and LCM datasets possess clearly attenuated expres-
sion levels in both the LCM and linear amplified bulk
microarrays. The loss of expression signal in the linear
amplified bulk data clearly indicates most of the observed
variations in gene expression are a by-product of a bias
arising from the amplification process. Only a small
number of probesets displayed variant expression
between the bulk and LCM microarrays, while displaying
consistent expression between the bulk and linear ampli-
fied bulk microarrays. These probesets may measure bio-
logically relevant variations of gene expression in the
samples acquired by LCM cell-sampling and bulk tissue-
sampling. However, these biologically relevant differences
in expression are obscured by the process bias and not eas-
ily identified when directly comparing amplified (LCM)
microarray data to unamplified (bulk) microarray data.
For most transcripts linear amplification is robust and
reproducible. However, for a subset of probesets a bias is
observed and may be at least partially explained by the
nucleotide sequence priming chemistry used in the ampli-
fication procedure [14]. Transcripts are initially amplified
using oligo dT primers from the 3' end. Following the first
round of amplification, a second round of amplification
is performed using random primers that hybridize any-
where along the length of the transcript, and initiate 5' to
3' sequence replication. This caused a disproportionate
accumulation of sequences representing the 3' end of the
Table 1: The overlap between the 603 probesets with clear amplification bias and probesets uniquely identified as upregulated or 
down-regulated in either the bulk or LCM dataset (but not both).
Dataset Unique Cancer-to-Normal Differentially Expressed Probesets
Bulk Upregulated
(N = 173)
Bulk Down-regulated
(N = 87)
LCM Upregulated
(N = 93)
LCM Down-regulated
(N = 313)
Probesets with Identified Amplification Bias (N = 603) 38 6 1 10BMC Medical Genomics 2009, 2:13 http://www.biomedcentral.com/1755-8794/2/13
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The concordance of differentially expressed probeset rankings between (a) LCM cell-sampling and bulk tissue-sampling data- sets at different levels of selection Figure 5
The concordance of differentially expressed probeset rankings between (a) LCM cell-sampling and bulk tissue-
sampling datasets at different levels of selection. For the top 10 and top 20 ranked probesets there is high concordance 
in upregulated probesets (~70%). Concordance levels for both upregulated and down-regulated probesets converge to ~58% 
for the top 100 ranked probesets. For the LCM, bulk, and linear amplified bulk samples (b), there is consistently strong con-
cordance between bulk and linear amplified bulk rankings of up- and down-regulated probesets (~75%). Concordance values 
are significantly lower for upregulated probesets between LCM and linear amplified bulk (~58%) or between LCM and bulk 
samples (~53%). The lowest concordance exists for the ranking of down-regulated probesets between LCM and either bulk or 
linear amplified bulk samples (~45%).
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transcripts compared with the 5' end. Longer transcripts
yield more skewing of transcript levels in the 3' end and a
higher 3'/5' ratios of in vitro synthesized RNA. Affymetrix
constructed the U133 Plus 2.0 microarray with probesets
located within 600 base pairs of the 3' end of the tran-
script http://www.affymetrix.com/support/technical/
technotes/hgu133_p2_technote.pdf. However, by map-
ping probeset positions to the target RefSeq transcripts, a
subset of probesets are found substantially further than
600 base-pairs from the 3' terminus. A density distribu-
tion of probeset to transcript 3' terminus distance, for
probesets with linear amplification bias and for a control
group of significantly expressed probesets, illustrates a sta-
tistically significant shift in the distribution curves (Figure
3). It is reasonable to conclude from these observations
that probeset to gene 3' end distance affects the validity of
linear amplified expression values. It is also reasonable to
conclude the biased amplified expression values do not
occur at random, but with a high-likelihood in the subset
of probesets located distant from the gene 3' end. There-
fore, any study using a linear amplification protocol with
random second round priming, should conduct a pilot
study to identify and correct for potential process bias.
The identification of genes with differential expression
between cancer and normal tissue is a common objective
of microarray studies and therefore was examined in this
study. The perceived value associated with LCM sampling
of a more specific population of cells than obtained by
bulk sampling, is realized in the selection of differentially
expressed probesets. It is clear from the comparisons
between the bulk, LCM, and linear amplified bulk data-
sets, LCM cell-sampling significantly effects the identifica-
tion of differential expression. The effect is most
pronounced for probesets with down-regulated expres-
sion in the cancer samples. Approximately twice as many
down-regulated probesets are found in the LCM datasets,
as found in either the bulk or linear amplified bulk data-
sets. The fact that this effect is not observed in the linear
amplified bulk microarrays supports the conclusion that
this is reflective of the cell population sampled and not a
prominent by-product of the previously discussed ampli-
fication bias. This is clearly illustrated in Figure 4b, where
the linear amplified findings align closely to the bulk find-
ings, but are quite different than those obtained from the
LCM data. The conclusion is further supported by the
results presented in Table 1, regarding comparisons made
to illustrate if the amplification bias was driving the
unique identification of up- or down-regulated probesets
in either the bulk or LCM datasets. Of the 313 down-reg-
ulated probesets found in the LCM samples and not in the
bulk samples, only 10 exhibited strong amplification bias.
The largest impact of the amplification bias was observed
in the upregulated probesets identified only in the bulk
dataset, where 38 of the 173 were affected. Examination of
the individual expression profiles for these probesets
reveals low expression values in the amplified samples. It
is apparent the increased expression in the cancer tissue,
observed in the bulk microarrays, is absent in the ampli-
fied samples as a result of the amplification process bias.
Individual expression profiles for those probesets
uniquely identified as down-regulated in the LCM dataset
were examined in the bulk and linear amplified bulk data-
sets. In most instances, the bulk and linear amplified bulk
expression profiles showed some down-regulation, sim-
ply not as prominent as that observed in the LCM data-
sets. Subsequently, these probesets were not counted as
down-regulated using the stringent criteria imposed in
this study. These observations imply LCM cell-sampling
provides a more sensitive method for identifying tran-
scripts which lose expression in cancer. Conversely, it
could be interpreted as the bulk tissue-sampling results in
a partial masking of the lost signal in the bulk dataset by
background expression in the contaminating cells. This
background expression signal would attenuate the level of
down-regulation observed in the bulk and linear ampli-
fied bulk datasets, leading to the skewed number of down-
regulated genes identified in the bulk and LCM datasets.
To provide a practical assessment of the impact LCM cell-
sampling has on the selection of candidate biomarkers,
concordance of the relative rankings of differentially up-
and down-regulated genes were evaluated. The impetus
for this analysis lies in the limited capacity of most
biomarker studies to validate and advance numerous dis-
coveries. While some projects are using more sophisti-
cated criteria for prioritizing biomarkers (i.e. systems
biology, pathways, genetic and epigenetic associations),
many investigators continue to use rankings based on the
magnitude of expression variation to prioritize candidate
gene lists. By determining the percent agreement between
LCM and bulk datasets, at various thresholds, it becomes
clear the differences in the differential genes selected are
fairly consistent throughout the rankings. As Figure 5a
illustrates, the concordance between LCM and bulk rank-
ings is approximately 55%. The only significant deviation
from this is in the highest ranked (top 20) up-regulated
genes, where a stronger concordance exists (~70%). Con-
cordance with the linear amplified bulk dataset, illus-
trated in Figure 5b, continues to show a consistent trend
of tight agreement between the bulk and linear amplified
bulk samples (~75%), with significantly lower correlation
between the two amplified datasets (40%–60%). This
supports the conclusion LCM cell-sampling provides a
unique molecular vantage in the selection of differentially
expressed genes, reflective of the cell population sampled.
The impact of LCM cell-sampling on the identification of
differentially expressed probesets observed in this studyBMC Medical Genomics 2009, 2:13 http://www.biomedcentral.com/1755-8794/2/13
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has been reported in other cancer studies [12,16,17]. A
study evaluating gene expression of in ER-α+ and ER-α-
breast cancer tumors found 30% more differential genes
using LCM cell-sampling than using bulk-tissue sampling
[16]. This difference is not as strong as observed in this
study, but it did involve the comparison of two sub-types
of tumor and not cancer to normal tissue. The Chinnaiyan
group found that LCM cell-sampling in prostate mini-
mized the strong contaminating influence of stromal
components and positively effected the selection of
down-regulated genes [17]. These results very closely
reflect what was observed in this study for lung, where the
LCM cell-sampling appears to minimize the noise level
caused by expression in contaminating cellular compo-
nents. A third study, on rectal carcinoma, found bulk tis-
sue-sampling to be more advantageous than LCM cell-
sampling [12]. A strong amplification bias was reported
on the gene expression profiles and a minimal effect of
stromal contamination on the expression data. These
findings may reflect tissue-specific effects, or reflect what
comparisons were preformed. The authors used cluster
analysis to determine many of the expression changes
observed in the study, and never did comparisons on the
selection of differential expression in the bulk and LCM
datasets. By not performing these comparisons, there was
no method for normalizing against amplification bias (by
comparing amplified-to-amplified data, with non-ampli-
fied-to-non-amplified data) and identifying the underly-
ing cell-sampling value found in the results presented in
this manuscript.
An interesting observation can be made when comparing
the results obtained by using different methods to directly
compare the bulk and LCM microarray data. When
defined thresholds are used to identify changes in expres-
sion between matched-sample microarrays, an average of
749 variant probesets were found in the normal samples
and 684 in the cancer samples. Similar but an expectedly
lower number of changes were found when comparing
group-average expression values (382 normal, 500 can-
cer). However, when the same comparisons were repeated
using a Bonferroni corrected T-test, a similar number of
variant probesets was identified in the normal tissue
(577), but considerably more were found in the cancer tis-
sue (3616). It appears this may be partially explained by
the relative sample size of the normal (n = 6) and cancer
(n = 10) sample sets. When a random selection of six can-
cer sample-pairs were analyzed using the Bonferroni-cor-
rected T-test, the number of variant probesets decreased
and approached the number found in the normal tissue
and by the defined threshold method (data not shown).
The sensitivity of the Bonferroni-corrected method to
sample size suggests a propensity towards identifying
modest changes in expression. With the relatively noisy
measurements obtained from microarrays, there is the risk
these modest changes in expression may fall within the
error bounds of the microarray platform, and be biologi-
cally irrelevant. The defined threshold method used in
this study was specifically designed with conservative cri-
teria, limiting selection to large, reproducible, changes in
expression, which are more likely to be experimentally
"real", and subsequently more robust to changes in sam-
ple size.
The linear amplified bulk microarray data generated in
this study may have more universal application to
researchers. Throughout these analyses, this data was used
to estimate the impact of the T7 amplification bias on the
expression values obtained from bulk tissue sampling and
LCM cell sampling (with amplification). While this study
specifically addressed lung samples, there may be broader
applicability of the amplified bulk expression data. Any
study using a similar amplification protocol coupled to
LCM-based microarray analyses may find this data useful
in interpreting the results. The amplification bias
described in this manuscript should be tissue-type inde-
pendent. Therefore, provided the gene under study is
expressed in the nascent sample, this data may be used to
test whether an apparently down-regulated transcript was
reflecting a potential amplification bias or a modified
expression state.
Conclusion
This study comparatively analyzed expression data gener-
ated from lung adenocarcinoma and adjacent normal tis-
sue acquired from the same samples using LCM cell-
sampling and bulk tissue-sampling. The results highlight
the importance that for any expression profiling study
using LCM cell-sampling, steps are taken to evaluate all
possible bias arising from the sample processing methods.
It is also evident from these analyses that restricting any
evaluation of acquisition methods to the comparison of
absolute expression level changes between the methods is
insufficient. The value of the acquisition method may
only be observed when relative changes in expression val-
ues are compared. In this study, all comparisons were
predicated on large changes in expression values. It is pos-
sible more value may be realized in LCM cell-sampling
when the dynamic range of expression profiling technol-
ogies improve and low level changes can be confidently
evaluated.
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